Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 1.00 |
| ▸ | ITGAV | P06756 | 19/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 8/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318113 | 0.89 | ITGB3 (0.80) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6326832 | 0.85 | ITGB3 (0.74) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6321791 | 0.84 | ITGB3 (0.72) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6319858 | 0.84 | ITGB3 (0.72) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6325089 | 0.84 | ITGB3 (0.72) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6319798 | 0.84 | ITGB3 (0.72) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6324900 | 0.83 | ITGB3 (0.70) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6326306 | 0.82 | ITGB3 (0.70) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL853051 | 0.82 | ITGB3 (0.69) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL853052 | 0.82 | ITGB3 (0.69) | ITGB3ITGAVITGB1ITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | claimed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | claimed |
| US-6949578-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2004-12-23 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| EP-1289960-A2 | CYCLOALKYL ALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
| WO-2001096307-A2 | CYCLOALKYL ALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | ADGRE5, ITGA5, ADGRF1 | ITGB3 5/4885ITGAV 7/4885ITGB1 8/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 6/4885ITGB1 5/4885 |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 7/4885ITGB1 6/4885 |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 7/4885ITGB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.